Kanker paru-paru mangrupikeun salah sahiji panyabab paling umum tina maotna manusa kusabab tumor, sareng tingkat morbiditas sareng mortalitasna parantos rengking kahiji di kota. Patologina utamana kanker paru sél non-leutik (NSCLC), kira-kira 85%. Kaseueuran pasien aya dina tahap tengah sareng akhir nalika didiagnosis, sareng 60 dugi ka 80% pasien kanker paru-paru kaleungitan kasempetan bedah nalika aranjeunna pasti didiagnosis. Dina waktos anu sami, bayah mangrupikeun organ kadua anu paling gampang métastatik tina tumor padet, dituturkeun ku metastasis ati. Pangobatan bedah sering dianggo pikeun pasien anu jumlah metastase terbatas sareng terbatas. Bedah merlukeun ngaleupaskeun bagian tina jaringan paru kalawan fungsi normal. Ku alatan éta, métode perlakuan anyar ogé diperlukeun pikeun ngaganti bedah.
In recent years, the minimally invasive radiofrequency ablation (RFA) technology has been used more and more as a minimally invasive treatment method in the treatment of primary / secondary lung tumors, and has made great progress, known as the treatment “Dinghaishen Needle” for kanker paru.
Naon ablasi frékuénsi radio?
Radiofrequency ablation consists of an electrode needle inserted into the tumor tissue and an electrode plate attached to the patient’s body to form a current loop. After the RF generator is turned on, high-frequency alternating current at the electrode tip is injected into the target tissue (Figure 2A), causing ions in the tissue to occur Shock, friction and heat generation will follow, causing cell death and coagulation necrosis in the target tissue around the electrode (Figure 2B). At the same time, the vascular tissue around the tumor will coagulate to form a reaction zone, preventing it from continuing to supply blood to the tumor and preventing tumor metastasis. Radio frequency waves can also cause tumor blood vessels to coagulate and reduce blood supply. At the same time, the ablated tumor tissue remains in the body. Due to its composition and structural changes, it can stimulate the body’s immunity and produce anti-tumor cytotoxic antibodies, and induce cytotoxic T cell immunity.
Kanker paru-paru mana anu dianggo ku RFA?
1. Used for kanker paru sél non-leutik that cannot tolerate surgery. Tumor diameter ≤2cm, 78 ~ 96% of patients can achieve complete ablation; tumor diameter ≤3cm, 5-year survival rate exceeds 50%. The treatment effect is better for primary lung cancer with a diameter ≤5cm.
2. For the treatment of lung metastases. Studies have shown that lung metastases with a diameter ≤2-3 cm, patients with lung metastases receiving RFA treatment have a 3-year survival rate of 53.7% and a 4-year survival rate of 44.1%. As shown in Figure 3, a kanker payudara patient relapsed with a single left lung metastasis. After RFA treatment, the follow-up and follow-up for nearly 3 years showed a good quality of life and no distant recurrence.
3. Pasén, awéwé, 48 taun, kalawan metastasis lung tunggal sanggeus bedah kanker payudara. Pikeun pengobatan penderita kanker paru sél non-leutik maju, kaasup inhibitor tirosin kinase (TKI), kayaning Kemena, Iressa atawa Trocaine sanggeus résistansi ubar lokal. Contona, terapi TKI geus jadi pilihan perlakuan lini kahiji pikeun penderita mutasi sénsitip reséptor faktor pertumbuhan épidermal (EGFR) maju dina kanker paru sél non-leutik maju. Pusat Panaliti Kanker Rumah Sakit Shao Yifu ngagunakeun téknologi RFA pikeun pengobatan paliatif kanker paru sél non-leutik sareng salah sahiji metode pengobatan alternatif pikeun ngatasi résistansi TKI.
4: A awéwé 59 taun heubeul kalawan kanker paru sél non-leutik canggih (mutasi EGFR) kalawan metastasis intra-pulmonal, 15 bulan sanggeus perlakuan TKI lisan, tumor paru katuhu handap (Gambar B) leuwih atra ti saméméhna. (Gambar A) sakumaha ditémbongkeun ku panah Ngaronjat, progression kasakit; CT-dipandu RFA perlakuan tina tumor lung katuhu handap (Gambar C), dituturkeun nepi pikeun 3 bulan (Gambar D), 6 bulan (Gambar E) némbongkeun kontrol alus.
4. Digabungkeun jeung kémoterapi jeung radiotherapy. Kémoterapi sareng radioterapi digabungkeun sareng terapi ablasi frekuensi radio dianggo pikeun tumor ati sareng paru métastatik. Aplikasi gabungan tina dua tiasa ngémutan kakurangan masing-masing sareng ningkatkeun éféktivitasna. Dibandingkeun sareng mode perawatan tunggal, éta manjangkeun waktos kasalametan pasien sareng ningkatkeun kualitas kahirupan.
The patient, a 58-year-old male, has colon cancer with multiple liver and lung metastases in the distance, making it difficult to operate and treat. Combined with chemotherapy and targeted drug therapy, especially combined with minimally invasive radiofrequency ablation technology, it successfully cured liver and lung metastases.
5. RFA can also be used for palliative treatment to relieve various discomfort symptoms of patients with advanced lung cancer.
6: Pasién kanker paru manula umur 88 taun kambuh sareng metastasis intra-pulmonal sareng pleural (ditémbongkeun dina Gambar A sareng B). Nyeri parna hese sare. Nyeri pasien sacara signifikan lega saatos pengobatan RFA tina tumor paru-paru, sareng kualitas sare sacara signifikan ningkat. Sanggeus sataun nuturkeun-up, sabar éta umumna dina kaayaan alus kalawan tumor paru stabil.
